Dextromethorphan and guaifenesin use should be monitored cautiously in people with "lousy metabolizer" CYP2D6 enzyme levels and patients who are sedated. This combination medication features a large median harmful dose (TD50) to median helpful dose (ED50) ratio (or therapeutic index) in these clients. We only use excellent, credible resources to https://chemicalglobe.com/